News

Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales — Update
Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.
NBC Los Angeles2h
Novo Nordisk cuts 2025 guidance as drug copycats hit Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk cuts 2025 guidance on weaker-than-expected Wegovy sales, posts first-quarter profit beat
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.
Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to DKK 78.1 billion in the first three months of 2025
Financial report for the period 1 January 2025 to 31 March 2025 Operating profit increased by 22% in Danish kroner and by 20% ...
Novo Nordisk Cuts Guidance as Copycat Versions of Ozempic Hit Sales
The company has seen sales hit by alternative compounded versions of its blockbuster weight-loss and diabetes drugs, ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share.
Not long ago the largest company by market capitalization in Europe, the evolution of the weight loss medicine market has ...